Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. [electronic resource]
Producer: 20170523Description: 1069-1077 p. digitalISSN:- 1532-1827
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzamides -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Crizotinib
- Drug Resistance, Neoplasm -- drug effects
- Erlotinib Hydrochloride -- administration & dosage
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Isoindoles -- administration & dosage
- Lung Neoplasms -- drug therapy
- Male
- Mice, Inbred BALB C
- Mice, SCID
- Neoadjuvant Therapy -- methods
- Neoplasm Recurrence, Local -- prevention & control
- Protein Kinase Inhibitors -- administration & dosage
- Pyrazoles -- administration & dosage
- Pyridines -- administration & dosage
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.